Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TREPULMIX 2,5 mg/ml SOLUCION PARA PERFUSION - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TREPULMIX 2,5 mg/ml SOLUCION PARA PERFUSION

Approved

STANDARD

TREPULMIX 2,5 mg/ml SOLUCION PARA PERFUSION

Scipharm S.À.R.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 7, 2021
Approval ID: 9bbcec4976a96d0e
Company: Scipharm S.À.R.L.
Type: Standard

Approval Details

Approval Id: 9bbcec4976a96d0e
Drug Cima Aemps Name: TREPULMIX 2,5 mg/ml SOLUCION PARA PERFUSION
Register Number: 1191419002
Holder Company Name: Scipharm S.À.R.L.
Marketing Company Name: Aop Orphan Pharmaceuticals Iberia, S.L.U
Authorization Date: 2021-04-07
Dosage Form: SOLUCIÓN PARA PERFUSIÓN
Dose: 2,5 mg/ml
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Scipharm S.À.R.L.

Active Ingredients

TREPROSTINILO SODICO

2,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 7, 2021

Approval ID

9bbcec4976a96d0e

Type

Standard

Back to CIMA-AEMPS Approvals